menu
    • menu
    [{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"ARS Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ARS Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Tai Tien Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Kissei Pharmaceutical \/ Tai Tien Pharmaceuticals"},{"orgOrder":0,"company":"Stallergenes Greer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"","graph1":"Immunology","graph2":"Approved FDF","graph3":"Stallergenes Greer","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Stallergenes Greer \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stallergenes Greer \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dydo Pharma","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amifampridine","moa":"Potassium channel","graph1":"Immunology","graph2":"Approved FDF","graph3":"Dydo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dydo Pharma \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dydo Pharma \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Approved FDF","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"IL-6","graph1":"Immunology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Keymed Gains Approval for Stapokibart in Seasonal Allergic Rhinitis Treatment

                            Details : Kangyueda (stapokibart) is a humanized and highly potent antibody against the IL-4Rα, indicated for treating Seasonal allergic rhinitis.

                            Product Name : Kangyueda

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 07, 2025

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celltrion

                            South Korea arrow
                            RNA Therapeutics
                            Not Confirmed

                            Celltrion

                            South Korea arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves Celltrion's Avtozma® (tocilizumab-anoh), a Biosimilar to Actemra

                            Details : FDA approvaed Avtozma, a biosimilar monoclonal antibody referencing Actemra, for moderate to severe active rheumatoid arthritis, systemic juvenile idiopathic arthritis, etc.

                            Product Name : Avtozma

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 31, 2025

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dydo Pharma

                            Japan arrow
                            RNA Therapeutics
                            Not Confirmed

                            Dydo Pharma

                            Japan arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

                            Details : Firdapse (amifampridine) is an oral, nonspecific, voltage-dependent, potassium channel blocker that is indicated to treat Lambert-Eaton myasthenic syndrome.

                            Product Name : Firdapse

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Amifampridine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Catalyst Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Atara Biotherapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Provides Update on Clinical Programs for EBVALLO™ and ATA3219

                            Details : FDA has placed a clinical hold on active IND applications of the EBVALLO (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with EBV+ PTLD.

                            Product Name : Ebvallo

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Atara Biotherapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

                            Details : Ebvallo (Tabelecleucel) is a gene therapy which is indicated as a monotherapy for the treatment of EBV-positive post-transplant lymphoproliferative disease.

                            Product Name : Ebvallo

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 16, 2025

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Incyte Corporation

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Axatilimab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Syndax Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Incyte and Syndax Announce FDA Approval of Niktimvo™ Vial Sizes

                            Details : Niktimvo (axatilimab) is an FDA approved monoclonal antibody that targets CSF-1R. It is approved for new strengths 9, 22 mg vials, for treating chronic graft-versus-host disease.

                            Product Name : Niktimvo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 15, 2025

                            Lead Product(s) : Axatilimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Syndax Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Stallergenes Greer

                            United Kingdom arrow
                            RNA Therapeutics
                            Not Confirmed

                            Stallergenes Greer

                            United Kingdom arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            European Commission Approves Palforzia® for Toddlers with Peanut Allergy

                            Details : Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.

                            Product Name : Palforzia

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : Arachis Hypogaea Allergen

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kissei Pharmaceutical

                            Japan arrow
                            RNA Therapeutics
                            Not Confirmed

                            Kissei Pharmaceutical

                            Japan arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Tai Tien Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mitsubishi Tanabe Pharma Signs Fostamatinib Sub-Licensing Agreement with Kissei

                            Details : Under the licensing agreement, Tai Tien will gain the rights to develop and commercialize Tavalisse (fostamatinib disodium hexahydrate) in Taiwan.

                            Product Name : Tavalisse

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Fostamatinib Disodium Hexahydrate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Tai Tien Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ARS Pharmaceuticals

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            ARS Pharmaceuticals

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ARS Files neffy® Approval in Canada, UK With ALK-Abelló A/S

                            Details : Neffy (epinephrine) is a nasal spray that acts as a adrenergic receptor agonist. It is approved for the treatment of Type I allergies, including anaphylaxis.

                            Product Name : Neffy

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth